In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled the median progression-free ...
Dec 8, 2022
0
6
Among premenopausal women with hormone receptor (HR)-positive, early-stage breast cancer enrolled in the SOFT trial, those with a high score on a genomic assay called Breast Cancer Index (BCI) had increased risk of distant ...
Dec 6, 2022
0
12
In patients with hormone receptor-positive, HER2-negative, advanced breast cancer—including patients with visceral crises—those treated with ribociclib plus endocrine therapy had fewer adverse events and a significantly ...
Dec 6, 2022
0
3
A Monash University-led trial of a new drug known as Q-122 therapy significantly reduced the number and severity of hot flashes and night sweats in women who have been diagnosed with breast cancer. It also improved their ...
Nov 11, 2022
0
31
Black women treated with neoadjuvant endocrine therapy for breast cancer were more likely to benefit than white women if treated at an earlier disease stage but less likely to benefit than white women if treated at a later ...
Sep 16, 2022
0
5
A research paper titled "A novel group of genes that cause endocrine resistance in breast cancer identified by dynamic gene expression analysis" was recently published in Oncotarget.
Jun 8, 2022
0
1
A large clinical trial has found that postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to as many as three lymph nodes and who ...
Dec 1, 2021
0
100
In the United States, apart from some forms of skin cancer, breast cancer is the most common cancer in women. It is also the most common cause of death from cancer among Hispanic women and the second most common among all ...
Dec 5, 2019
0
1
(HealthDay)—Endocrine therapy reduces the quality of life of breast cancer patients, especially for postmenopausal women, according to a study recently published in the Annals of Oncology.
Nov 25, 2019
0
3
According to the latest GLOBOCAN cancer database, New Zealand's breast cancer incidence rate is among the highest in the world. It affects one in nine women in their lifetime and accounts for almost half of all cancers for ...
Mar 1, 2019
0
24
